| Tracy James Robinson, MD | |
|
1947 E Sycamore Ln, Holladay, UT 84117-5130 | |
| (952) 595-1100 | |
| (612) 294-4903 |
| Full Name | Tracy James Robinson |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 20 Years |
| Location | 1947 E Sycamore Ln, Holladay, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689998924 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 325622-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Mark's Hospital | Salt lake city, UT | Hospital |
| Ogden Regional Medical Center | Ogden, UT | Hospital |
| Lakeview Hospital | Bountiful, UT | Hospital |
| Lone Peak Hospital | Draper, UT | Hospital |
| Mountain West Medical Center | Tooele, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Utah Imaging Associates Inc | 1355394537 | 43 |
| Tooele Valley Imaging Llc | 2466624630 | 19 |
| Green River Radiology Pc | 5294123063 | 26 |
News Archive
Recently, researchers from the Monash University and Monash Medical Centre, Clayton, Victoria, Australia, investigated whether peptide sensitization using BCG can produce cross-reactive T cells specific to SARS-CoV-2. Their study is published on the preprint server, medRxiv.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
According to a new report by researchers from UK, the population of Papua New Guinea has the greatest linguistic and genetic diversity. The language differences across the bends of the river Sepik are baffling and reflect and underlying genetic diversity that was until now not fully appreciated. The study report is published today 15th of September 2017 in the journal Science.
Type II diabetes and Parkinson's disease may not appear to have much in common but a look below the surface reveals important molecular similarities that provide a potential target for fighting Parkinson's.
› Verified 5 days ago
| Entity Name | Utah Imaging Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629076229 PECOS PAC ID: 1355394537 Enrollment ID: O20050228000845 |
News Archive
Recently, researchers from the Monash University and Monash Medical Centre, Clayton, Victoria, Australia, investigated whether peptide sensitization using BCG can produce cross-reactive T cells specific to SARS-CoV-2. Their study is published on the preprint server, medRxiv.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
According to a new report by researchers from UK, the population of Papua New Guinea has the greatest linguistic and genetic diversity. The language differences across the bends of the river Sepik are baffling and reflect and underlying genetic diversity that was until now not fully appreciated. The study report is published today 15th of September 2017 in the journal Science.
Type II diabetes and Parkinson's disease may not appear to have much in common but a look below the surface reveals important molecular similarities that provide a potential target for fighting Parkinson's.
› Verified 5 days ago
| Entity Name | Radadvantage A Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376719666 PECOS PAC ID: 2163597899 Enrollment ID: O20100505001083 |
News Archive
Recently, researchers from the Monash University and Monash Medical Centre, Clayton, Victoria, Australia, investigated whether peptide sensitization using BCG can produce cross-reactive T cells specific to SARS-CoV-2. Their study is published on the preprint server, medRxiv.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
According to a new report by researchers from UK, the population of Papua New Guinea has the greatest linguistic and genetic diversity. The language differences across the bends of the river Sepik are baffling and reflect and underlying genetic diversity that was until now not fully appreciated. The study report is published today 15th of September 2017 in the journal Science.
Type II diabetes and Parkinson's disease may not appear to have much in common but a look below the surface reveals important molecular similarities that provide a potential target for fighting Parkinson's.
› Verified 5 days ago
| Entity Name | Tooele Valley Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699004499 PECOS PAC ID: 2466624630 Enrollment ID: O20111012000146 |
News Archive
Recently, researchers from the Monash University and Monash Medical Centre, Clayton, Victoria, Australia, investigated whether peptide sensitization using BCG can produce cross-reactive T cells specific to SARS-CoV-2. Their study is published on the preprint server, medRxiv.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
According to a new report by researchers from UK, the population of Papua New Guinea has the greatest linguistic and genetic diversity. The language differences across the bends of the river Sepik are baffling and reflect and underlying genetic diversity that was until now not fully appreciated. The study report is published today 15th of September 2017 in the journal Science.
Type II diabetes and Parkinson's disease may not appear to have much in common but a look below the surface reveals important molecular similarities that provide a potential target for fighting Parkinson's.
› Verified 5 days ago
| Entity Name | Oquirrh Radiology Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568734143 PECOS PAC ID: 4082875448 Enrollment ID: O20120411000273 |
News Archive
Recently, researchers from the Monash University and Monash Medical Centre, Clayton, Victoria, Australia, investigated whether peptide sensitization using BCG can produce cross-reactive T cells specific to SARS-CoV-2. Their study is published on the preprint server, medRxiv.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
According to a new report by researchers from UK, the population of Papua New Guinea has the greatest linguistic and genetic diversity. The language differences across the bends of the river Sepik are baffling and reflect and underlying genetic diversity that was until now not fully appreciated. The study report is published today 15th of September 2017 in the journal Science.
Type II diabetes and Parkinson's disease may not appear to have much in common but a look below the surface reveals important molecular similarities that provide a potential target for fighting Parkinson's.
› Verified 5 days ago
| Entity Name | Green River Radiology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508533878 PECOS PAC ID: 5294123063 Enrollment ID: O20211027002062 |
News Archive
Recently, researchers from the Monash University and Monash Medical Centre, Clayton, Victoria, Australia, investigated whether peptide sensitization using BCG can produce cross-reactive T cells specific to SARS-CoV-2. Their study is published on the preprint server, medRxiv.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
According to a new report by researchers from UK, the population of Papua New Guinea has the greatest linguistic and genetic diversity. The language differences across the bends of the river Sepik are baffling and reflect and underlying genetic diversity that was until now not fully appreciated. The study report is published today 15th of September 2017 in the journal Science.
Type II diabetes and Parkinson's disease may not appear to have much in common but a look below the surface reveals important molecular similarities that provide a potential target for fighting Parkinson's.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tracy James Robinson, MD 11995 Singletree Ln, Ste 500, Eden Prairie, MN 55344-5347 Ph: (952) 595-1301 | Tracy James Robinson, MD 1947 E Sycamore Ln, Holladay, UT 84117-5130 Ph: (952) 595-1100 |
News Archive
Recently, researchers from the Monash University and Monash Medical Centre, Clayton, Victoria, Australia, investigated whether peptide sensitization using BCG can produce cross-reactive T cells specific to SARS-CoV-2. Their study is published on the preprint server, medRxiv.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
According to a new report by researchers from UK, the population of Papua New Guinea has the greatest linguistic and genetic diversity. The language differences across the bends of the river Sepik are baffling and reflect and underlying genetic diversity that was until now not fully appreciated. The study report is published today 15th of September 2017 in the journal Science.
Type II diabetes and Parkinson's disease may not appear to have much in common but a look below the surface reveals important molecular similarities that provide a potential target for fighting Parkinson's.
› Verified 5 days ago